BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.
The virtual event featured company executives and external expert Dmitriy Zamarin. Martin Welschof, president and CEO, opened the session and outlined the agenda covering the treatment landscape and company progress.
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
Researchers led by Umeå University pathologist Maréne Landström report that a fully human antibody aimed at an oncogenic form of TGF‑β receptor I (TβRI) signaling suppressed tumor growth and metastasis in preclinical models of advanced prostate cancer. The study was published in Signal Transduction and Targeted Therapy.
Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.
Ti AI ṣe iroyin
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.
Ti AI ṣe iroyin
Researchers at Weill Cornell Medicine have developed tiny silica nanoparticles that destroyed aggressive prostate cancer tumors in mice while boosting the immune system. The treatment led to complete remissions when combined with immunotherapy.